Cutting off the power: inhibition of leukemia cell growth by pausing basal ATP release and P2X receptor signaling?

Purinergic Signalling

Volumn 12, Issue 3, 2016, Pages 439-451

  Ledderose, Carola ^a   Woehrle, Tobias ^a   Ledderose, Stephan ^a   Strasser, Katharina ^a   Seist, Richard ^a   Bao, Yi ^a   Zhang, Jingping ^a   Junger, Wolfgang G ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Jurkat T cells; Mitochondria; P2X receptors; Proliferation; Purinergic signaling; T lymphocytes

Indexed keywords

ADENOSINE TRIPHOSPHATE; PURINERGIC P2X RECEPTOR; RESAZURIN; RESORUFIN; REACTIVE OXYGEN METABOLITE;

ARTICLE; CELL PROLIFERATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROLYSIS; LEUKEMIA CELL; MEMBRANE POTENTIAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPECTRAL SENSITIVITY; CALCIUM SIGNALING; JURKAT CELL LINE; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; PATHOLOGY; PHYSIOLOGY; SECRETION (PROCESS); T CELL LEUKEMIA; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; CALCIUM SIGNALING; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; JURKAT CELLS; LEUKEMIA, T-CELL; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, PURINERGIC P2X;

EID: 84961644581     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-016-9510-y     Document Type: Article

References (54)

1. Siegel R, Ma J, Zou Z, Jemal A (2008) Cancer statistics, 2014. CA Cancer J Clin 64:9–29
2. Pui CH, Robison LL, Look AT (2008) Acute lymphoblastic leukaemia. Lancet 371:1030–1043
3. Pui CH (2009) T cell acute lymphoblastic leukemia: NOTCHing the way toward a better treatment outcome. Cancer Cell 15:85–87
4. Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM (2012) Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood 119:34–43
5. Riscoe MK, Brouns MC, Fitchen JH (1989) Purine metabolism as a target for leukemia chemotherapy. Blood Rev 3:162–173
6. Poplack DG, Blatt J, Reaman G (1981) Purine pathway enzyme abnormalities in acute lymphoblastic leukemia. Cancer Res 41:4821–4823
7. Zimmermann H, Zebisch M, Sträter N (2012) Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal 8:437–502
8. Junger WG (2011) Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol 11:201–212
9. Filippini A, Taffs RE, Sitkovsky MV (1990) Extracellular ATP in T-lymphocyte activation: possible role in effector functions. Proc Natl Acad Sci U S A 87:8267–8271
10. Schenk U, Westendorf AM, Radaelli E, Casati A, Ferro M, Fumagalli M, Verderio C, Buer J, Scanziani E, Grassi F (2008) Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci Signal 1(39):ra6
11. Yip L, Woehrle T, Corriden R, Hirsh M, Chen Y, Inoue Y, Ferrari V, Insel PA, Junger WG (2009) Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J 23:1685–1693
12. Woehrle T, Yip L, Elkhal A, Sumi Y, Chen Y, Yao Y, Insel PA, Junger WG (2010) Pannexin-1 hemichannel-mediated ATP release together with P2X1 and P2X4 receptors regulate T-cell activation at the immune synapse. Blood 116:3475–3484
13. Ledderose C, Bao Y, Lidicky M, Zipperle J, Li L, Strasser K, Shapiro NI, Junger WG (2014) Mitochondria are gate-keepers of T cell function by producing the ATP that drives purinergic signaling. J Biol Chem 289:25936–25945
14. Yip L, Cheung CW, Corriden R, Chen Y, Insel PA, Junger WG (2007) Hypertonic stress regulates T-cell function by the opposing actions of extracellular adenosine triphosphate and adenosine. Shock 27:242–250
15. Sumi Y, Woehrle T, Chen Y, Bao Y, Li X, Yao Y, Inoue Y, Tanaka H, Junger WG (2014) Plasma ATP is required for neutrophil activation in a mouse sepsis model. Shock 42:142–147
16. Kurishita Y, Kohira T, Ojida A, Hamachi I (2012) Organelle-localizable fluorescent chemosensors for site-specific multicolor imaging of nucleoside polyphosphate dynamics in living cells. J Am Chem Soc 134:18779–18789
17. Ledderose C, Bao Y, Ledderose S, Woehrle T, Heinisch M, Yip L, Zhang J, Robson SC, Shapiro NI, Junger WG (2016) Mitochondrial dysfunction depletes purinergic signaling mechanisms needed for T cell vigilance and immune defense. J Infect Dis 213:456–464
18. Zhi-Jun Y, Sriranganathan N, Vaught T, Arastu SK, Ahmed SA (1997) A dye-based lymphocyte proliferation assay that permits multiple immunological analyses: mRNA, cytogenetic, apoptosis, and immunophenotyping studies. J Immunol Methods 210:25–39
19. Albini A, Sporn MB (2007) The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 7:139–147
20. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, Huang X, Caldwell S, Liu K, Smith P, Chen JF, Jackson EK, Apasov S, Abrams S, Sitkovsky M (2006) A2A adenosine receptor protects tumors from anti-tumor T cells. Proc Natl Acad Sci U S A 103:13132–13137
21. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F (2008) Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS ONE 3(7), e2599
22. Yegutkin GG, Mikhailov A, Samburski SS, Jalkanen S (2006) The detection of micromolar pericellular ATP pool on lymphocyte surface by using lymphoid ecto-adenylate kinase as intrinsic ATP sensor. Mol Biol Cell 17:3378–3385
23. Warburg O (1956) On the origin of cancer cells. Science 123:309–314
24. Pendergrass W, Wolf N, Poot M (2004) Efficacy of MitoTracker Green and CMXrosamine to measure changes in mitochondrial membrane potentials in living cells and tissues. Cytometry A 61:162–169
25. Keij JF, Bell-Prince C, Steinkamp JA (2000) Staining of mitochondrial membranes with 10-nonyl acridine orange, MitoFluor Green, and MitoTracker Green is affected by mitochondrial membrane potential altering drugs. Cytometry 39:203–210
26. Burnstock G, Fredholm BB, North RA, Verkhratsky A (2010) The birth and postnatal development of purinergic signaling. Acta Physiol 199:93–147
27. White N, Burnstock G (2006) P2 receptors and cancer. Trends Pharmacol Sci 27:211–217
28. Burnstock G, Di Virgilio F (2013) Purinergic signaling and cancer. Purinergic Signal 9:491–540
29. Antonioli L, Blandizzi C, Pacher P, Hasko G (2013) Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev 13:842–857
30. Di Virgilio F, Ferrari D, Adinolfi E (2009) P2X7: a growth-promoting receptor—implications for cancer. Purinergic Signal 5:251–256
31. Baricordi OR, Melchiorri L, Adinolfi E, Falzoni S, Chiozzi P, Buell G, Di Virgilio F (1999) Increased proliferation rate of lymphoid cells transfected with the P2X(7) ATP receptor. J Biol Chem 274:33206–33208
32. Zhang XJ, Zheng GG, Ma XT, Yang YH, Li G, Rao Q, Nie K, Wu KF (2004) Expression of P2X7 in human hematopoietic cell lines and leukemia patients. Leuk Res 28:1313–1322
33. Adinolfi E, Melchiorri L, Falzoni S, Chiozzi P, Morelli A, Tieghi A, Cuneo A, Castoldi G, Di Virgilio F, Baricordi OR (2002) P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood 99:706–708
34. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033
35. Weinberg SE, Chandel NS (2015) Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol 11:9–15
36. Wallace DC (2012) Mitochondria and cancer. Nat Rev Cancer 12:685–698
37. Zu XL, Guppy M (2004) Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun 313:459–465
38. Bao Y, Ledderose C, Seier T, Graf AF, Brix B, Chong E, Junger WG (2014) Mitochondria regulate neutrophil activation by generating ATP for autocrine purinergic signaling. J Biol Chem 289:26794–26803
39. Bao Y, Ledderose C, Graf AF, Brix B, Birsak T, Lee A, Zhang J, Junger WG (2015) mTOR and differential activation of mitochondria orchestrate neutrophil chemotaxis. J Cell Biol 210:1153–1164
40. Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M et al (2015) Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 22:58–73
41. Voogd TE, Vansterkenburg ELM, Wilting J, Janssen LHM (1993) Recent research on the biological activity of suramin. Pharmacol Rev 45:177–203
42. La Rocca RV, Danesi R, Cooper MR, Jamis-Dow CA, Ewing MW, Linehan WM, Myers CE (1991) Effect of suramin on human prostate cancer cells in vitro. J Urol 145:393–398
43. Taylor CW, Lui R, Fanta P, Salmon SE (1992) Effects of suramin on in vitro growth of fresh human tumors. J Natl Cancer Inst 84:489–494
44. Rubio GJ, Pinedo HM, Virizuela J, van Ark-Otte J, Giaccone G (1995) Effects of suramin on human lung cancer cell lines. Eur J Cancer 31A:244–251
45. Hosang M (1985) Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem 29:265–273
46. Pollak M, Richard M (1990) Suramin blockade of insulin-like growth factor I-stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst 82:1349–1352
47. Figg WD, Cooper MR, Thibault A, Headlee D, Humphrey J, Bergan RC, Reed E, Sartor O (1994) Acute renal toxicity associated with suramin in the treatment of prostate cancer. Cancer 74:1612–1614
48. Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O (1995) Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 76:452–463
49. Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M (2000) Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 18:1440–1450
50. Beavis PA, Stagg J, Darcy PK, Smyth MJ (2012) CD73: a potent suppressor of antitumor immune response. Trends Immunol 33:231–237
51. Antonioli L, Blandizzi C, Pacher P, Haskó G (2013) Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 13:842–857
52. Robak P, Robak T (2013) Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treat Rev 39:851–861
53. Salam L, Abdel-Wahab O (2015) Hairy cell leukemia: update and current therapeutic approach. Curr Opin Hematol 22:355–361
54. Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B, Wang T, Chen WW, Clish CB, Sabatin DM (2014) Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 508:108–112